Intraday Trading Highlights
SPARC opened the day with a notable gap-up of 7.99%, signalling strong buying interest from the outset. Throughout the trading session, the stock maintained upward momentum, eventually touching its peak at Rs 148.1, representing an 11.1% gain intraday. By the close, the stock recorded a day change of 10.77%, substantially outperforming the Pharmaceuticals & Biotechnology sector, which gained 2.87% on the same day.
The stock’s performance also eclipsed the broader market benchmark, with the Sensex closing down by 2.91% at 84,045.87 points after an initial gap-up opening of 3,656.74 points. This divergence highlights SPARC’s relative strength amid a market that saw profit-taking and a loss of momentum in large-cap indices.
Technical Positioning and Moving Averages
SPARC’s price action remains technically strong, trading above all key moving averages including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This alignment suggests sustained short- to long-term bullishness in the stock’s price structure. The stock’s ability to hold above these technical levels during a volatile market session underscores its resilience.
In contrast, the Sensex was trading below its 50-day moving average, although the 50-day average itself remains above the 200-day average, indicating a longer-term uptrend for the benchmark despite short-term weakness.
Relative Performance Across Timeframes
SPARC’s recent performance metrics reveal a pattern of outperformance relative to the Sensex across multiple time horizons. Over the past day, the stock gained 8.78% compared to the Sensex’s 2.86%. Over one week, SPARC surged 17.46%, significantly ahead of the Sensex’s 2.62% rise. The one-month gain of 6.62% also contrasts with the Sensex’s decline of 2.05% during the same period.
However, longer-term returns remain subdued, with the stock down 6.75% over one year and showing negative returns over three, five, and ten years, contrasting with the Sensex’s strong gains of 8.83%, 38.07%, 67.15%, and 246.78% respectively over those periods. This indicates that while SPARC has demonstrated recent strength, it continues to face challenges in regaining its longer-term growth trajectory.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Sector and Market Context
The Pharmaceuticals & Biotechnology sector, to which SPARC belongs, recorded a gain of 2.87% on the day, supported by selective buying in key stocks. SPARC’s outperformance by 7.91% relative to its sector peers highlights its distinct trading strength.
Meanwhile, the broader market environment was mixed. The Sensex, after a strong gap-up opening, lost momentum and closed lower by 2.91%. Mega-cap stocks led the market’s gains, but the overall index remained 2.51% below its 52-week high of 86,159.02 points. This divergence between SPARC’s performance and the broader market underscores the stock’s unique intraday strength.
Mojo Score and Market Capitalisation Grade
SPARC currently holds a Mojo Score of 1.0, categorised as a Strong Sell, reflecting cautious sentiment based on fundamental and momentum factors. This rating was downgraded from Sell on 1 Feb 2024. The stock’s market capitalisation grade stands at 3, indicating a mid-tier market cap within its sector.
Despite the strong intraday price action, these metrics suggest that the stock’s overall quality and momentum remain under scrutiny, which may influence trading behaviour in the near term.
Summary of Price Movements and Trading Action
On 3 Feb 2026, SPARC’s price opened at a premium, quickly gaining 7.99% from the previous close. The stock’s intraday high of Rs 148.1 represented an 11.1% increase, with the session closing at a 10.77% gain. This performance was supported by sustained buying interest, as evidenced by the stock’s position above all major moving averages.
The stock’s outperformance relative to both its sector and the Sensex highlights its strong intraday momentum, even as the broader market experienced a pullback. This trading action reflects a focused demand for SPARC shares during the session, distinguishing it from the general market trend.
Sun Pharma Advanced Research Company Ltd or something better? Our SwitchER feature analyzes this small-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Conclusion
Sun Pharma Advanced Research Company Ltd’s strong intraday performance on 3 Feb 2026, marked by an 11.1% intraday high and a 10.77% closing gain, stands out amid a broader market retreat. The stock’s ability to outperform its sector and the Sensex, while maintaining a position above key moving averages, highlights its current trading strength.
While the Mojo Score and longer-term performance metrics indicate a cautious outlook, the day’s price action reflects focused demand and robust momentum in the stock. This session’s trading behaviour will be closely watched for indications of sustained strength or potential volatility in the near term.
Unlock special upgrade rates for a limited period. Start Saving Now →
